Workflow
Lexaria Bioscience(LEXX) - 2024 Q2 - Quarterly Report
LEXXLexaria Bioscience(LEXX)2024-04-10 04:12

For the transition period from [ ] to [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) Commission file number 000-52138 Nevada 20-2000871 LEXARIA BIOSCIENCE CORP. (State or other jur ...